DR info

Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166

Drugs and their primary sponsors and trial info

00070500
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
00319301
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
   Center for International Blood and Marrow Transplant Research
      2011   -   NCT01351545   United States;
AD-MSC transdifferentiated HSCs (AD-HSCs)
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China;
AMG531
   Kyowa Hakko Kirin Co., Ltd.
      2016   Phase 2-3   JPRN-JapicCTI-163243   -
   Kyowa Kirin Co., Ltd
      2019   Phase 2-3   JPRN-JapicCTI-194962   Japan, Asia except Japan;
      2019   Phase 2-3   JPRN-JapicCTI-194746   Japan, Asia except Japan;
   Kyowa Kirin Korea Co., Ltd.
      2014   Phase 2   NCT02094417   Korea, Republic of;
AMPHOTERICINE B, LIPOSOME
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain;
AP1903
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      2017   Phase 1;Phase 2   EUCTR2016-003226-16-IT   Italy;
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom;
AP1903 A594
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
ATG
   Chinese Academy of Medical Sciences
      2010   Phase 4   NCT01997372   China;
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00001964   United States;
   University of Illinois at Chicago
      2000   -   NCT01499147   United States;
ATG+Rapamune+cyclosporine
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00061360   United States;
ATG+cyclosporine
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00061360   United States;
ATGAM plus CsA with or without Eltrombopag
   European Society for Blood and Marrow Transplantation
      2021   -   NCT05049668   France;
Abatacept
   Emory University
      2014   Phase 1   NCT01917708   United States;
Adipose derived mesenchymal stem cells ( AD-MSCs)
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China;
Alefacept
   Emory University
      2010   -   NCT01319851   United States;
   The Cleveland Clinic
      2011   Phase 1   NCT01267643   United States;
Alemtuzumab
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   Federico II University
      2006   Phase 2   NCT00895739   Italy;
   GCP-ISS HE0403 group
      2004   Phase 1,2   JPRN-C000000356   Japan;
   M.D. Anderson Cancer Center
      2010   Phase 2   NCT01191749   United States;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States;
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2007   -   EUCTR2008-001151-22-IT   Italy;
Alemtuzumab (Campath )
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00195624   United States;
Alemtuzumab and Rituximab
   Hospital Universitario Dr. Jose E. Gonzalez
      2011   -   NCT01408342   Mexico;
Alkeran
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
Allogeneic Bone Marrow Transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States;
Allogeneic Hematopoietic Stem Cell Transplantation
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03192397   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Allogeneic donor derived B-lymphocytes
   University of Erlangen-Nürnberg Medical School
      2013   Phase 1/Phase 2   NCT02007811   Germany;
Allogeneic hematopoietic stem cell transplantation
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States;
Allogeneic stem cell transplant
   St. Jude Children's Research Hospital
      2002   -   NCT00186797   United States;
Allogenic Stem Cell Transplantation
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
Alpha beta depletion
   Mitchell Cairo
      2020   Phase 2   NCT04099966   United States;
Androgens
   Shengyun Lin
      2018   -   NCT03218657   China;
Anti-CD45
   Baylor College of Medicine
      2001   Phase 1/Phase 2   NCT00590460   United States;
Anti-Thymocyte Globulin
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States;
      2012   Phase 2   NCT01624805   United States;
Anti-Thymocyte Globulin (Rabbit)
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
Anti-human T-lymphocyte immunoglobulin from horse
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan;
Anti-human immunoglobulin, equine
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan;
Anti-thymocyte globulin
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of;
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of;
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
      2000   Phase 2   NCT00006379   United States;
      1998   Phase 2   NCT00003336   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
      2006   Phase 1   NCT00354419   United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States;
   Roswell Park Cancer Institute
      2009   -   NCT00856388   United States;
      2002   Phase 2   NCT00053989   United States;
      1998   Phase 3   NCT00004474   United States;
      1998   Phase 2/Phase 3   NCT00003816   United States;
   The Cleveland Clinic
      2005   Phase 2   NCT01231841   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Anti-thymocyte globulin (horse)
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States;
Anti-thymocyte globulin (rabbit)
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom;
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom;
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00260689   United States;
Antilymphocyte serum
   National Heart, Lung, and Blood Institute (NHLBI)
      1982   Phase 3   NCT00000597   -
Antithymocyte Globulin
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States;
      2000   -   NCT00427336   United States;
Antithymocyte Globulin (ATG)
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
Antithymocyte globulin
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      1997   Phase 2   NCT00001626   United States;
Antithymocyte globulin (Rabbit)
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States;
Antiviral therapy
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
Apheresis
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 1   NCT00011830   United States;
Assessment of therapy complications
   Vanderbilt University
      2009   -   NCT00993694   United States;
Atgam
   Pfizer Inc.
      -   Phase 3   EUCTR2021-002155-11-Outside-EU/EEA   Japan;
Avatrombopag
   Peking Union Medical College Hospital
      2021   Phase 2/Phase 3   NCT04728789   China;
BL-8040
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States;
BPX-501 cells
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      2014   Phase 1;Phase 2   EUCTR2014-000584-41-IT   Italy;Spain;United Kingdom;
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Bone Marrow Transplant
   M.D. Anderson Cancer Center
      2006   Phase 1/Phase 2   NCT00474747   United States;
Bone marrow ablation with stem cell support
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States;
Bone marrow aspiration
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States;
Bone marrow derived mesenchymal stem cells
   Guangzhou General Hospital of Guangzhou Military Command
      2011   Phase 1/Phase 2   NCT01305694   China;
Bone marrow transplant
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States;
Bone marrow transplantation
   Roswell Park Cancer Institute
      1998   Phase 3   NCT00004474   United States;
Busilvex
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
Busulfan
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States;
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States;
   Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
      2017   Phase 0   ChiCTR1900023509   China;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States;
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States;
Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
   University of California, San Francisco
      2002   Phase 2   NCT00516152   United States;
CAMPATH-1H
   Baylor College of Medicine
      2001   Phase 1/Phase 2   NCT00590460   United States;
CAMPATH-1H (Alemtuzumab)
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States;
CASPOFUNGIN ACETATE
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain;
CD3-depleted hematopoietic cell transplantation
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of;
CD34 Stem Cell Selection Therapy
   Diane George
      2013   Phase 1/Phase 2   NCT01966367   United States;
CD3±CD19 depleted hematopoietic stem cell transplantation
   Asan Medical Center
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of;
CD45RA-depleted DLI
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
CD62L- Tem
   University College, London
      2019   Phase 1   NCT03836690   United Kingdom;
CEFEPIME DIHYDROCHLORIDE MONOHYDRATE
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain;
CYCLOPHOSPHAMIDE MONOHYDRATE
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
Campath
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States;
Campath 1H
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Campath, Chemo and/or TBI Allo SCT
   David Rizzieri, MD
      1999   Phase 2   NCT00004143   United States;
Campath-1H
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States;
Carboplatin
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States;
Carmustine
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
Chelation
   Novartis Pharmaceuticals
      2014   Phase 4   NCT01818726   Russian Federation;
Chemotherapy
   Vanderbilt University
      2009   -   NCT00993694   United States;
Chinese herbal concoction twice a day for 6 months
   Singapore General Hospital
      2009   Phase 1/Phase 2   NCT01224496   Singapore;
Ciclosporin
   Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Sciences
      2021   Phase 0   ChiCTR2100045322   China;
   Jiangsu Province Hospital
      2020   Phase 4   ChiCTR2100045895   China;
Ciclosporin Soft Capsule
   Jiangsu HengRui Medicine Co., Ltd.
      2020   Phase 1   NCT05088174   China;
Ciclosporine
   Blood Diseases Hospital, Chinese Academy of Medical Sciences
      2015   Phase 1 study   ChiCTR-IPR-14005720   China;
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
CliniMACS
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
CliniMACS device
   Memorial Sloan Kettering Cancer Center
      2009   Phase 2   NCT00987480   United States;
Clofarabine
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States;
Cohort 2: hATG, CsA, EPAG Day 14 to Month 3
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States;
Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States;
Combination of thrombopoietin mimetic and cyclosporin A
   Safaa AA Khaled
      2019   Phase 4   NCT03896971   Egypt;
Cord Blood Infusion
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
Cord Blood Transplant
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01553461   United States;
Cord Blood Units
   National Heart, Lung, and Blood Institute (NHLBI)
      2015   Phase 2   NCT01861093   United States;
Cord blood
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China;
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China;
CordIn
   National Heart, Lung, and Blood Institute (NHLBI)
      2017   Phase 1/Phase 2   NCT03173937   United States;
Creatinine
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   Japan;
CsA
   Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
      2017   -   JPRN-UMIN000030453   Japan;
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Henan Province Cancer Hospital
      2017   -   ChiCTR-IOR-17012957   China;
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   Japan;
   Jiangsu Province Hospital
      2020   Phase 4   ChiCTR2100045895   China;
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China;
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
      2015   Phase 2   NCT02404025   Japan;
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China;
Cy
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China;
Cy-ATG
   Cooperative Study Group A for Hematology
      2010   Phase 3   NCT01145976   Korea, Republic of;
Cyclophosphamide
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of;
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of;
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States;
      1999   Phase 2   NCT00636909   -
   Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital
      2019   Phase 0   ChiCTR1900026462   China;
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
      2000   Phase 2   NCT00006379   United States;
      1998   Phase 2   NCT00003336   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
      2006   Phase 2   NCT00343785   Canada;United States;
      2006   Phase 1   NCT00354419   United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan;
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States;
      2017   Phase 1   NCT02960646   United States;
      2006   Phase 1/Phase 2   NCT00474747   United States;
      2000   -   NCT00427336   United States;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2007   Phase 2/Phase 3   NCT00455312   United States;
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
      2006   Phase 1/Phase 2   NCT00326417   United States;
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States;
      1995   Phase 2   NCT00002718   United States;
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2019   Phase 2   NCT03520647   United States;
      2010   Phase 1/Phase 2   NCT01193283   United States;
      2010   Phase 1/Phase 2   NCT01187017   United States;
      1997   Phase 2   NCT00001626   United States;
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States;
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
      2017   Phase 2   NCT03192397   United States;
      2002   Phase 2   NCT00053989   United States;
      1998   Phase 3   NCT00004474   United States;
      1998   Phase 2/Phase 3   NCT00003816   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
      2010   Phase 2   NCT01350245   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States;
      2014   Phase 2   NCT02224872   United States;
      1996   Phase 2   NCT00004464   United States;
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
   University of Alabama at Birmingham
      2013   Phase 2   NCT02065154   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
   Xiangya Hosptial of Central South University
      2017   -   ChiCTR-ONC-17012896   China;
Cyclophosphamide (CY)
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States;
Cyclophosphamide (CY) (Plan 1)
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
Cyclophosphamide (CY) (Plan 2)
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
Cyclophosphamide, Fludarabine, Rabbit ATG
   City of Hope Medical Center
      2009   -   NCT01129323   United States;
Cyclophosphamide, Fludarabine, Thymoglobulin
   The Korean Society of Pediatric Hematology Oncology
      2008   Phase 2   NCT00882323   Korea, Republic of;
Cyclophosphamide, fludarabine , thymoglobulin
   The Korean Society of Pediatric Hematology Oncology
      2006   Phase 2   NCT00737685   Korea, Republic of;
Cyclophosphamide,Campath IH and TBI
   Mayo Clinic
      2007   Phase 1   NCT00578266   United States;
Cyclophosphamide,cyclosporine A
   Xiaofan Zhu
      2012   Phase 4   NCT01995331   China;
Cyclosporin
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States;
   The First Affiliated Hospital of Zhengzhou University
      2016   -   ChiCTR-IOR-16008738   China;
Cyclosporin A
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
   Peking Union Medical College Hospital
      2020   Phase 2   NCT04403321   China;
   Shandong University
      2010   Phase 2   NCT01182662   China;
Cyclosporine
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States;
   Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
      2017   -   JPRN-UMIN000030453   Japan;
   Federico II University
      2006   Phase 2   NCT00895739   Italy;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
      2006   Phase 1   NCT00354419   United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
      2021   Phase 2   ChiCTR2100043229   China;
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China;
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
      2021   Phase 4   ChiCTR2000041485   China;
   Jinhua people's Hospital
      2015   Phase 2-3   ChiCTR1900028153   -
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States;
      2005   Phase 2   NCT00806598   United States;
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States;
      2010   Phase 1/Phase 2   NCT01193283   United States;
      2005   Phase 2   NCT00260689   United States;
      2005   Phase 2   NCT00195624   United States;
      2000   Phase 2   NCT00005935   United States;
      1997   Phase 2   NCT00001626   United States;
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT02998645   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
   Office of Rare Diseases (ORD)
      2006   Phase 1/Phase 2   NCT00319878   United States;
   The Cleveland Clinic
      2005   Phase 2   NCT01231841   United States;
Cyclosporine (Gengraf )
   National Heart, Lung, and Blood Institute (NHLBI)
      2009   Phase 2   NCT00944749   United States;
Cyclosporine A
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00001964   United States;
Cyclosporine A (CsA)
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan;
Cyclosporine Oral Product
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China;
Cyclosporins
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   Shengyun Lin
      2018   -   NCT03218657   China;
Cytarabine
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China;
Cytokine-treated Veto Cells
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States;
Cytoxan
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States;
DNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
      2006   Phase 1   NCT00354419   United States;
Daclizumab
   Neal Young, M.D.
      1999   Phase 2   NCT00001962   United States;
Danazol
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China;
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College
      2021   Phase 4   ChiCTR2000041485   China;
   National Heart, Lung, and Blood Institute (NHLBI)
      2011   Phase 1/Phase 2   NCT01441037   United States;
Dapsone
   Vanderbilt University
      2009   -   NCT00993694   United States;
Decitabine
   Institute of Hematology & Blood Diseases Hospital
      2021   Phase 2   NCT04854889   China;
   The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
      2021   Phase 0   ChiCTR2100047288   China;
Desferasirox
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01546415   China;
Dextrose
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan;
Donor Lymphocyte Infusion
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
Donor Lymphocyte Infusion (DLI)
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States;
      2010   Phase 2   NCT01350245   United States;
Donor mobilized PBSC infusion
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
EDTA
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan;
ELTROMBOPAG OLAMINE
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Italy;Netherlands;Switzerland;
ENBREL*SC 4FL 25MG+4SIR 1ML
   ISTITUTO GIANNINA GASLINI
      2009   -   EUCTR2009-012746-23-IT   Italy;
      2005   -   EUCTR2004-004914-18-IT   Italy;
ETB115
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
   Novartis Farmacéutica, S.A
      2017   Phase 2   EUCTR2016-002814-29-ES   Brazil;Canada;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Qatar;Spain;Turkey;
   Novartis Pharma AG
      2019   Phase 2   EUCTR2015-003166-91-GB   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
      2018   Phase 2   EUCTR2015-003166-91-NL   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002814-29-NL   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
      2017   Phase 2   EUCTR2016-002814-29-HU   Brazil;France;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Turkey;
      2017   Phase 2   EUCTR2015-003166-91-PT   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
Early retreatment with ATG
   European Group for Blood and Marrow Transplantation
      2001   Phase 3   NCT01163942   Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
Eltrombopag
   Assiut University
      2017   Phase 4   NCT03243656   Egypt;
   B. Höchsmann
      2015   Phase 2/Phase 3   NCT02773225   Germany;
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 3   NCT03413306   Russian Federation;
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States;
      2013   Phase 2   NCT01891994   United States;
      2011   Phase 2   NCT01328587   United States;
      2009   Phase 2   NCT00922883   United States;
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan;
      2019   Phase 2   NCT03988608   China;
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
      2017   Phase 2   NCT02998645   Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
      2015   Phase 2   NCT02404025   Japan;
      2014   Phase 2   NCT02148133   Japan;
   University of Utah
      2012   Phase 2   NCT01703169   United States;
Etanercept
   ISTITUTO GIANNINA GASLINI
      2009   -   EUCTR2009-012746-23-IT   Italy;
      2005   -   EUCTR2004-004914-18-IT   Italy;
Etoposide
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States;
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
Extension Cohort
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 1/Phase 2   NCT01623167   United States;
FK-506
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States;
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
FLUDARABINE PHOSPHATE
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
Filgrastim
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of;
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of;
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States;
      2012   Phase 2   NCT01624805   United States;
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      1996   Phase 2   NCT00004464   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Flu-ATG
   Cooperative Study Group A for Hematology
      2010   Phase 3   NCT01145976   Korea, Republic of;
Fludarabine
   Asan Medical Center
      2012   Phase 2   NCT01759732   Korea, Republic of;
      2009   Phase 1/Phase 2   NCT01105273   Korea, Republic of;
   Baylor College of Medicine
      2001   Phase 1/Phase 2   NCT00590460   United States;
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States;
      1999   Phase 2   NCT00636909   -
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   GCP-ISS HE0403 group
      2004   Phase 1,2   JPRN-C000000356   Japan;
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan;
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States;
      2006   Phase 1/Phase 2   NCT00474747   United States;
      2000   -   NCT00427336   United States;
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
      2007   Phase 2/Phase 3   NCT00455312   United States;
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
      2006   Phase 1/Phase 2   NCT00326417   United States;
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States;
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 1/Phase 2   NCT01187017   United States;
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States;
   Peking University People's Hospital
      2018   -   NCT03821987   China;
   Seoul National University Hospital
      2011   Phase 2   NCT01472055   Korea, Republic of;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
      2011   Phase 2   NCT01384513   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States;
      2014   Phase 2   NCT02224872   United States;
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
Fludarabine (FLU)
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
Fludarabine Phosphate
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
      2017   Phase 2   NCT03192397   United States;
Fludarabine phosphate
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
      2000   Phase 2   NCT00006379   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
      2002   Phase 2   NCT00053989   United States;
      1998   Phase 2/Phase 3   NCT00003816   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Fludarabine, Cyclophosphamide
   St. Jude Children's Research Hospital
      2002   -   NCT00186797   United States;
Fludarabine/ melphalan
   University of Illinois at Chicago
      2000   -   NCT01499147   United States;
Fludarabine/busulfan
   University of Illinois at Chicago
      2000   -   NCT01499147   United States;
Foscarnet
   The First Affiliated Hospital of Zhejiang University School of Medicine
      2020   Phase 0   ChiCTR2000031933   China;
Foscarnet sodium
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
G-CSF
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   European Group for Blood and Marrow Transplantation
      2001   Phase 3   NCT01163942   Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom;
   Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences
      2019   Phase 0   ChiCTR1900027553   China;
   M.D. Anderson Cancer Center
      2005   Phase 2   NCT00806598   United States;
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 2   NCT01174108   United States;
      2001   Phase 1   NCT00011830   United States;
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
GM-CSF
   Beth Israel Deaconess Medical Center
      2002   Phase 2   NCT00533923   United States;
GVHD Prophylaxis
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
Ganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
Graft-versus-tumor induction therapy
   Case Comprehensive Cancer Center
      2000   Phase 2   NCT00006379   United States;
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
H-ATG (ATGAM )
   National Heart, Lung, and Blood Institute (NHLBI)
      2009   Phase 2   NCT00944749   United States;
HATG
   European Group for Blood and Marrow Transplantation
      2015   Phase 3   NCT02099747   France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT03025698   Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom;United States;
HPC, A Infusion
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY
   Regeneron Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-GB   France;Korea, Republic of;United Kingdom;United States;
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-FR   France;Korea, Republic of;United Kingdom;United States;
Haplo HSCT
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
Haplo/cord transplant
   Joanne Kurtzberg, MD
      2007   Phase 1/Phase 2   NCT00673114   United States;
Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2018   Phase 2   NCT03955601   Pakistan;
Haploidentical Hematopoietic Cell Transplantation
   Johns Hopkins All Children's Hospital
      2020   Phase 2   NCT04356469   United States;
Hematopoietic Cell Transplantation
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
Hematopoietic stem cell transplantation (HSCT)
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2010   Phase 2   NCT01350245   United States;
Heparin
   Alberta Children's Hospital
      2011   Phase 3   NCT01343680   Canada;
Hetrombopag
   Peking Union Medical College Hospital
      2021   Phase 2/Phase 3   NCT05018936   China;
Hetrombopag Olamine
   Jiangsu HengRui Medicine Co., Ltd.
      2019   Phase 3   NCT04961710   China;
      2018   Phase 1/Phase 2   NCT03557099   China;
Hetrombopag Olamine Tablet
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT05088655   China;
      2020   Phase 1   NCT05088642   China;
      2020   Phase 1   NCT05088174   China;
Hetrombopag Olamine+Standard Therapy
   Jiangsu HengRui Medicine Co., Ltd.
      2019   Phase 3   NCT03825744   China;
Horse anti-thymocyte globulin (ATG)
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
Horse anti-thymocyte globulin (hATG)
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States;
Horse-Anti-thymocyte-Globulin
   National Heart, Lung, and Blood Institute (NHLBI)
      2020   Phase 2   NCT04304820   United States;
Human Placental Derived Stem Cell
   New York Medical College
      2013   Phase 1   NCT01586455   United States;
ICL670
   Novartis Pharmaceuticals
      2014   Phase 4   NCT01818726   Russian Federation;
IST (ATG + CsA)
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 3   NCT03413306   Russian Federation;
Ibrutinib
   Jennifer Woyach
      2020   Phase 2   NCT04439006   United States;
Imipenem / cilastatine
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands;
Imipenem-cilastatine
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands;
Immunosuppressive Therapy (IST)
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
In vitro-treated bone marrow transplantation
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
In vitro-treated peripheral blood stem cell transplantation
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
Infection prophylaxis and management
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
Intravenous bone marrow mesenchymal stem cells infusion
   University of Sao Paulo
      2011   Phase 1/Phase 2   NCT01297972   Brazil;
Itacitinib
   Incyte Corporation
      2019   -   NCT03906318   -
Levamisole
   The First affiliated Hospital of Zhejiang Chinese Medical University
      2017   -   ChiCTR-IOR-17011653   China;
Levamisole hydrochloride
   Shengyun Lin
      2018   -   NCT03218657   China;
Levamisole+cyclosporin A+Glucocorticoids
   Institute of Hematology & Blood Diseases Hospital
      2013   Phase 2   NCT01760096   China;
      2012   Phase 2   NCT01642979   China;
Lo-Ovral Oral Contraceptive Pills
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2007   Phase 1/Phase 2   NCT00556400   United States;
MMF
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan;
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00001964   United States;
MPA
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan;
MSC
   CHU Sart-Tilman
      2009   Phase 3   EUCTR2008-005594-35-BE   Belgium;
MSC+ATG
   Chinese Academy of Medical Sciences
      2013   Phase 4   NCT02218437   China;
MTX
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
Management of therapy complications
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
Mannitol
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom;
Matched Unrelated Donor Hematopoietic Stem Cell Transplant
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
Melphalan
   Case Comprehensive Cancer Center
      1998   Phase 2   NCT00003336   United States;
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2009   -   NCT00856388   United States;
      1998   Phase 2/Phase 3   NCT00003816   United States;
   Texas Oncology Cancer Center
      2011   Phase 2   NCT01500161   United States;
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
Melphalan Hydrochloride
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03192397   United States;
Mesenchymal stem cells
   CHU Sart-Tilman
      2009   Phase 3   EUCTR2008-005594-35-BE   Belgium;
   Guangzhou General Hospital of Guangzhou Military Command
      2013   Phase 2   NCT02247973   China;
   Hebei Medical University
      2017   Phase 1   NCT03055078   China;
Mesna
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States;
   St. Jude Children's Research Hospital
      2021   Phase 2   NCT04558736   United States;
   University of Rochester
      2015   Phase 1   NCT03016806   United States;
Metformin
   Department of Hematology, Second Medical Center, Chinese PLA General Hospital
      2020   Phase 2   ChiCTR2000028833   China;
Methotrexate
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States;
   Beth Israel Deaconess Medical Center
      1999   Phase 2   NCT00636909   -
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
   Xiangya Hosptial of Central South University
      2017   -   ChiCTR-ONC-17012896   China;
Methylprednisolone
   BioLineRx, Ltd.
      2015   Phase 2   NCT02462252   United States;
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
      1998   Phase 2   NCT00003336   United States;
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   Japan;
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States;
      2005   Phase 2   NCT00806598   United States;
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004323   United States;
   Northwestern Memorial Hospital
      2001   -   NCT00017654   United States;
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
Methylprednisolone (MP)
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
Miltenyi CD34 Reagent System
   National Heart, Lung, and Blood Institute (NHLBI)
      2010   Phase 2   NCT01174108   United States;
Muromonab-CD3
   H. Lee Moffitt Cancer Center and Research Institute
      1996   Phase 2   NCT00005852   -
Mycophenolate Mofetil (MMF)
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2010   Phase 2   NCT01350245   United States;
Mycophenolate mofetil
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00005935   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2002   Phase 2   NCT00053989   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
      2011   Phase 2   NCT01384513   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Mycophenolate mofetil (MMF)
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
Mycophenolic acid
   Kobe University Graduate School of Medicine
      2010   -   JPRN-UMIN000004264   Japan;
Mycophenolic acid mofetil
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2014   Phase 2   NCT02224872   United States;
Nandrolone
   National Heart, Lung, and Blood Institute (NHLBI)
      1982   Phase 3   NCT00000597   -
Neoral
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
Non ATG Conditioning regimen
   Assiut University
      2019   Phase 2/Phase 3   NCT03295058   -
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Normal saline
   Alberta Children's Hospital
      2011   Phase 3   NCT01343680   Canada;
Noxafil Gastro resistant tablets
   King's College Hospital NHS Foundation Trust
      2016   Phase 4   EUCTR2016-001223-31-GB   United Kingdom;
Noxafil®
   King's College Hospital NHS Foundation Trust
      2016   Phase 4   EUCTR2016-001223-31-GB   United Kingdom;
Obatoclax mesylate (GX15-070MS)
   Gemin X
      2005   Phase 1   NCT00438178   Canada;United States;
PF-06462700
   Pfizer
      2020   Phase 3   NCT04350606   Japan;
Pegfilgrastim
   M.D. Anderson Cancer Center
      2012   Phase 2   NCT01624805   United States;
Peripheral Blood Stem Cell Transplantation
   M.D. Anderson Cancer Center
      2019   Phase 1/Phase 2   NCT03622788   United States;
      2017   Phase 1   NCT02960646   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
Peripheral blood stem cell transplantation
   Case Comprehensive Cancer Center
      2000   Phase 2   NCT00006379   United States;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2002   Phase 2   NCT00053989   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Peripheral blood stem cell transplantation (PBSCT)
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2011   Phase 2   NCT01384513   United States;
Posaconazole
   King's College Hospital NHS Trust
      2016   Phase 4   NCT02875743   United Kingdom;
   Seoul National University Hospital
      2018   Phase 2   NCT03318159   Korea, Republic of;
Prednisolone
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   Japan;
Prograf
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
R-ATG
   National Heart, Lung, and Blood Institute (NHLBI)
      2003   Phase 2   NCT00065260   United States;
RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
RATG
   Ishiyama Ken
      2019   Phase 2   JPRN-jRCTs071190032   Japan;
REGN7257
   Regeneron Pharmaceuticals
      2021   Phase 1/Phase 2   NCT04409080   France;Korea, Republic of;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-GB   France;Korea, Republic of;United Kingdom;United States;
      2020   Phase 1;Phase 2   EUCTR2020-002031-29-FR   France;Korea, Republic of;United Kingdom;United States;
REVOLADE - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU) 28 COMPRESSE
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
REVOLADE - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
RNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
RVG 101614
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands;
RVG 105155
   VU University Medical Center
      2015   Phase 4   EUCTR2014-001546-25-NL   Netherlands;
Rabbit ATG
   Northside Hospital, Inc.
      2016   Phase 2   NCT02828592   United States;
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02404025   Japan;
Rabbit ATG, (Genzyme)
   Jinan Military General Hospital
      2017   Phase 4   NCT02838992   China;
Rabbit ATG, Cyclosporine, Levamisole
   Yizhou Zheng
      2014   Phase 2   NCT02203396   China;
Rabbit ATG, Thymoglobuline (Genzyme)
   King Faisal Specialist Hospital & Research Center
      2008   Phase 2   NCT01530555   -
Rabbit anti-thymocyte globulin (ATG)
   Michael Pulsipher, MD
      2016   -   NCT02845596   United States;
Rabbit anti-thymocyte globulin (r-ATG)
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04328727   China;Japan;Korea, Republic of;Taiwan;
Rabbit antithymocyte globulin
   European Group for Blood and Marrow Transplantation
      2008   Phase 2   NCT00471848   France;Germany;Italy;Saudi Arabia;Switzerland;United Kingdom;
Rabbit antithymoglobulin (ATG)
   Navy General Hospital, Beijing
      2015   Phase 1/Phase 2   NCT02407470   China;
Rapamune
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
Rapamycin
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
   National Heart, Lung, and Blood Institute (NHLBI)
      1993   Phase 1   NCT00001398   United States;
Revolade
   European Society for Blood and Marrow Transplantation
      2015   -   EUCTR2014-000363-40-ES   Spain;
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Italy;Netherlands;Switzerland;
RhTPO
   Institute of Hematology, People's Hospital, Peking University
      2019   -   ChiCTR1800019669   China;
   Tianjin Medical University General Hospital
      2016   Phase 2   NCT02857530   China;
Rimiducid
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Rituxan
   Memorial Sloan Kettering Cancer Center
      2018   Phase 1   NCT03531736   United States;
Rituximab
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States;
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2005   Phase 2   NCT00229619   United States;
Rivogenlecleucel
   Bellicum Pharmaceuticals, Inc.
      -   Phase 2   EUCTR2014-000584-41-GB   Italy;Spain;United Kingdom;
Rivogenleucleucel
   Bellicum Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2014-000584-41-ES   Italy;Spain;United Kingdom;
Romiplostim
   Anjali Sharathkumar
      2020   Early Phase 1   NCT04478227   United States;
   Kyowa Hakko Kirin Co., Ltd.
      2016   Phase 2-3   JPRN-JapicCTI-163243   -
   Kyowa Kirin Co., Ltd
      2019   Phase 2-3   JPRN-JapicCTI-194962   Japan, Asia except Japan;
      2019   Phase 2-3   JPRN-JapicCTI-194746   Japan, Asia except Japan;
   Kyowa Kirin Co., Ltd.
      2019   Phase 2/Phase 3   NCT04095936   Japan;
      2019   Phase 2/Phase 3   NCT03957694   Japan;
      2016   Phase 2/Phase 3   NCT02773290   Japan;Korea, Republic of;
SA
   The First affiliated Hospital of Zhejiang Chinese Medical University
      2017   -   ChiCTR-IOR-17011653   China;
SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
SANDIMMUN NEORAL - 25 MG CAPSULE MOLLI 50 CAPSULE
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
SANDIMMUN NEORAL - 50 MG CAPSULE MOLLI 50 CAPSULE
   NOVARTIS PHARMA AG
      2019   Phase 2   EUCTR2016-002814-29-IT   Brazil;Hong Kong;Hungary;India;Italy;Korea, Democratic People's Republic of;Mexico;Netherlands;Spain;Thailand;Turkey;
SB497115
   Universitätsklinikum Ulm
      2015   Phase 2;Phase 3   EUCTR2014-000174-19-DE   France;Germany;Italy;Netherlands;Switzerland;
SODIUM CHLORIDE SOLUTION
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
SULFAMETH
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain;
Sandimmun Neoral
   Karolinska Institutet
      2007   -   EUCTR2006-006577-25-SE   Finland;Sweden;
Sargramostim
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
      2002   -   NCT00053157   United States;
Sirolimus
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2016   Phase 2   NCT02979873   United States;
   Office of Rare Diseases (ORD)
      2006   Phase 1/Phase 2   NCT00319878   United States;
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03192397   United States;
Sodium chloride
   EBMT (European group for Blood and Marrow Transplantation)
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom;
Standard Vitamin D3 Supplementation
   Phoenix Children's Hospital
      2017   Phase 4   NCT03176849   United States;
Standard therapy of septic shock
   National Research Center for Hematology, Russia
      2012   Phase 1/Phase 2   NCT01849237   Russian Federation;
Stanozolol
   The First Affiliated Hospital of Zhengzhou University
      2016   -   ChiCTR-IOR-16008738   China;
Stem Cell Transplant
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States;
Stem Cell Transplantation
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Stem cell infusion
   Baylor College of Medicine
      2002   Phase 2   NCT00578903   United States;
      2001   Phase 1/Phase 2   NCT00590460   United States;
T Cell-Depleted Donor Lymphocyte Infusion
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
TRIMETHOPRIM SULFATE
   José Miguel Cisneros Herreros
      2012   Phase 3   EUCTR2011-005152-34-ES   Spain;
Tacrolimus
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States;
   M.D. Anderson Cancer Center
      2017   Phase 1   NCT02960646   United States;
   Medical College of Wisconsin
      2017   Phase 2   NCT02918292   United States;
   Peking Union Medical College Hospital
      2020   Phase 2   NCT04403321   China;
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States;
      2002   Phase 2   NCT00053989   United States;
   Sidney Kimmel Cancer Center at Thomas Jefferson University
      2015   Phase 2   NCT02566304   United States;
      2011   Phase 2   NCT01384513   United States;
      2010   Phase 2   NCT01350245   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States;
      2014   Phase 2   NCT02224872   United States;
   Thomas Jefferson University
      2021   Phase 2   NCT05031897   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Testosterone undecanoate
   Jinhua people's Hospital
      2015   Phase 2-3   ChiCTR1900028153   -
Therapeutic allogeneic lymphocytes
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
   University of California, San Francisco
      2005   -   NCT00295997   United States;
Thiotepa
   Memorial Sloan Kettering Cancer Center
      1995   Phase 2   NCT00002718   United States;
   Roswell Park Cancer Institute
      1998   Phase 2/Phase 3   NCT00003816   United States;
Thymoglobulin
   Kanto Study Group for Cell Therapy
      2011   Phase 2   JPRN-UMIN000006071   Japan;
   King's College Hospital NHS Foundation Trust
      2008   Phase 2   EUCTR2007-001657-26-GB   United Kingdom;
   M.D. Anderson Cancer Center
      2005   Phase 2   NCT00806598   United States;
   Nagoya University
      2012   Phase 3   NCT01844635   Japan;
      2012   -   JPRN-UMIN000011134   Japan,Asia(except Japan);
   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
      2016   Phase 4   NCT02745717   China;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2016   Phase 2   NCT02833805   United States;
      2014   Phase 2   NCT02224872   United States;
Thymoglobuline®/Thymoglobulin®
   EBMT (European Group for Blood and Marrow Transplantation)
      2009   -   EUCTR2007-000902-55-DE   France;Germany;United Kingdom;
   EBMT (European group for Blood and Marrow Transplantation)
      2008   -   EUCTR2007-000902-55-FR   France;Germany;United Kingdom;
      2007   Phase 2   EUCTR2007-000902-55-GB   France;Germany;United Kingdom;
Total Body Irradiation
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States;
Total Body Irradiation (TBI) (Plan 1)
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States;
Umbilical Cord Blood
   National Heart, Lung, and Blood Institute (NHLBI)
      2008   Phase 2   NCT00604201   United States;
Umbilical Cord Blood After Myeloablative Conditioning
   Tufts Medical Center
      2005   Phase 2   NCT00676806   United States;
Umbilical Cord Blood After Reduced-Intensity Conditioning
   Tufts Medical Center
      2005   Phase 2   NCT00676806   United States;
Umbilical Cord Blood Transplantation
   New York Blood Center
      1993   Early Phase 1   NCT00212407   United States;
Umbilical cord blood transplantation
   Case Comprehensive Cancer Center
      2002   Phase 1   NCT00054236   United States;
      1998   Phase 2   NCT00003336   United States;
   Fred Hutchinson Cancer Research Center
      2006   Phase 1   NCT00354419   United States;
   Roswell Park Cancer Institute
      2002   Phase 2   NCT00053989   United States;
Valganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
Voriconazole
   Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
      2013   -   ChiCTR-PRC-13003130   China;
polymerase chain reaction
   City of Hope Medical Center
      2010   -   NCT01199562   United States;
polymorphism analysis
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00343785   Canada;United States;
protein expression analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States;